Company intelligence / Profile preview

Nucelis

San Diego, California, United Statesnucelis.com ↗

Ownership: Private
Development stage: Other

Overview

Nucelis has developed a proprietary non-transgenic gene-editing platform to engineer microbial strains for high-value specialty ingredient production. Its lead product is ergosterol/vitamin D2 produced from engineered Yarrowia lipolytica yeast. Commercial samples have been available since 2023. The company operates through partnerships and licensing agreements with downstream manufacturers.

Therapeutic areas: Endocrinology
Modalities: Microbial fermentationGene-edited yeast strainsMetabolic engineering
Industry: Non-Drug Biotech

Partnerships

Fermic S.A. de C.V. (fermentation/manufacturing partner in Mexico)Nanjing Darwingenetech Co., Ltd. (Chinese manufacturing/customer development partner)

Beyond the preview

Go deeper on Nucelis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucelis.

Explore the full profile